Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.
For this indication, competent medicine agencies globally authorize below treatments:
For: Newborns Infants Children Adolescents
Subcutaneous
35 - 35 ug per kg of body weight
From 35 To 35 ug per kg of body weight once every day
Generally a dose of 0.035 mg/kg body weight per day is recommended. Daily doses of 2.7 mg should not be exceeded. Treatment should not be used in children with a growth velocity of less than 1 cm per year and near closure of epiphyses.
The injection should be given subcutaneously and the site varied to prevent lipoatrophy.
For: Newborns Infants Children Adolescents
Subcutaneous
1 - 1 mg per m² of body surface area (BSA)
From 1 To 1 mg per m² of body surface area (BSA) once every day
Generally a dose of 1.0 mg/m² body surface area per day is recommended. Daily doses of 2.7 mg should not be exceeded. Treatment should not be used in children with a growth velocity of less than 1 cm per year and near closure of epiphyses.
The injection should be given subcutaneously and the site varied to prevent lipoatrophy.